Collaboraive sharing of molecules and data in the mobile ageSean Ekins
An overview of using collaborative software in small and large scale collaborations in drug discovery. A focus on Tuberculosis. Also analysis of collaboration and mobile apps for science
The structure elucidation of natural product structures from analytical data, specifically NMR and MS, remains a major challenge. With an enormous palette of NMR experiments to choose from, and supported by breakthrough technologies in hardware, the generation of high quality data to enable even the most complex of natural product structures to be determined is no longer the major hurdle. The challenge is in the analysis of the data. We are in a new era in terms of approaches to structure elucidation: one where computers, databases, and a synergy between scientists and algorithms can offer an accelerated path forward. Software tools are capable of digesting spectroscopic data to elucidate extremely complex natural products. Scientists can now elucidate chemical structures utilizing multinuclear chemical shift data, correlation data from an array of 2D NMR experiments and utilize existing data sets for the purpose of dereplication and computer-assisted structure elucidation. With the explosion of online data especially, in public databases such as PubChem and ChemSpider, many tens of millions of chemical structures are available to seed fragment databases to include in the elucidation process. This presentation will provide an overview of how cheminformatics and chemical databases have been brought together to assist in the identification of natural products. It will include an examination of the state-of-the-art developments in Computer-Assisted Structure Elucidation.
The development of QSAR models is critically dependent on the quality of available data. As part of our efforts to develop public platforms to provide access to predictive models, we have attempted to discriminate the influence of the quality versus quantity of data available to develop and validate QSAR models. We have focused our efforts on the widely used EPISuite software that was initially developed over two decades ago and, specifically, on the PHYSPROP dataset used to train the EPISuite prediction models. This presentation will review our approaches to examining key datasets, the delivery of curated data and the development of machine-learning models for thirteen separate property endpoints of interest to environmental science. We will also review how these data will be made freely accessible to the community via a new “chemistry dashboard”. This abstract does not reflect U.S. EPA policy
In the late Fall and Winter of 2018, the Pistoia Alliance in cooperation with Elsevier and charitable organizations Cures within Reach and Mission: Cure ran a datathon aiming to find drugs suitable for treatment of childhood chronic pancreatitis, a rare disease that causes extreme suffering. The datathon resulted in identification of four candidate compounds in a short time frame of just under three months. In this webinar our speakers discuss the technologies that made this leap possible
Collaboraive sharing of molecules and data in the mobile ageSean Ekins
An overview of using collaborative software in small and large scale collaborations in drug discovery. A focus on Tuberculosis. Also analysis of collaboration and mobile apps for science
The structure elucidation of natural product structures from analytical data, specifically NMR and MS, remains a major challenge. With an enormous palette of NMR experiments to choose from, and supported by breakthrough technologies in hardware, the generation of high quality data to enable even the most complex of natural product structures to be determined is no longer the major hurdle. The challenge is in the analysis of the data. We are in a new era in terms of approaches to structure elucidation: one where computers, databases, and a synergy between scientists and algorithms can offer an accelerated path forward. Software tools are capable of digesting spectroscopic data to elucidate extremely complex natural products. Scientists can now elucidate chemical structures utilizing multinuclear chemical shift data, correlation data from an array of 2D NMR experiments and utilize existing data sets for the purpose of dereplication and computer-assisted structure elucidation. With the explosion of online data especially, in public databases such as PubChem and ChemSpider, many tens of millions of chemical structures are available to seed fragment databases to include in the elucidation process. This presentation will provide an overview of how cheminformatics and chemical databases have been brought together to assist in the identification of natural products. It will include an examination of the state-of-the-art developments in Computer-Assisted Structure Elucidation.
The development of QSAR models is critically dependent on the quality of available data. As part of our efforts to develop public platforms to provide access to predictive models, we have attempted to discriminate the influence of the quality versus quantity of data available to develop and validate QSAR models. We have focused our efforts on the widely used EPISuite software that was initially developed over two decades ago and, specifically, on the PHYSPROP dataset used to train the EPISuite prediction models. This presentation will review our approaches to examining key datasets, the delivery of curated data and the development of machine-learning models for thirteen separate property endpoints of interest to environmental science. We will also review how these data will be made freely accessible to the community via a new “chemistry dashboard”. This abstract does not reflect U.S. EPA policy
In the late Fall and Winter of 2018, the Pistoia Alliance in cooperation with Elsevier and charitable organizations Cures within Reach and Mission: Cure ran a datathon aiming to find drugs suitable for treatment of childhood chronic pancreatitis, a rare disease that causes extreme suffering. The datathon resulted in identification of four candidate compounds in a short time frame of just under three months. In this webinar our speakers discuss the technologies that made this leap possible
With the explosion of interest in both enhanced knowledge management and open science, the past few years have seen considerable discussion about making scientific data “FAIR” — findable, accessible, interoperable, and reusable. The problem is that most scientific datasets are not FAIR. When left to their own devices, scientists do an absolutely terrible job creating the metadata that describe the experimental datasets that make their way in online repositories. The lack of standardization makes it extremely difficult for other investigators to locate relevant datasets, to re-analyse them, and to integrate those datasets with other data. The Center for Expanded Data Annotation and Retrieval (CEDAR) has the goal of enhancing the authoring of experimental metadata to make online datasets more useful to the scientific community. The CEDAR work bench for metadata management will be presented in this webinar. CEDAR illustrates the importance of semantic technology to driving open science. It also demonstrates a means for simplifying access to scientific data sets and enhancing the reuse of the data to drive new discoveries.
Considerations and challenges in building an end to-end microbiome workflowEagle Genomics
Many of the data management and analysis challenges in microbiome research are shared with genomics and other life-science big-data disciplines. However there are aspects that are specific: some are intrinsic to microbiome data, some are related to the maturity of the field, with others related to extracting business value from the data.
The phrase “Big Data” is generally used to describe a large volume of structured and/or unstructured data that cannot be processed using traditional database and software techniques. In the domain of chemistry the Royal Society of Chemistry certainly hosts large structured databases of chemistry data, for example ChemSpider, as well as unstructured content, in the form of our collection of scientific articles. Our research literature provides value to their readership and, at present, as an example of one of our databases, ChemSpider is accessed by many tens of thousands of scientists every day. But do these collections constitute “Big Data” or is it the potential which lies within the collections that can contribute to the Big Data movement. This presentation will discuss our activities to contribute both data, and service-based access to our data sets, to support grant-based projects such as the Innovative Medicines Initiative Open PHACTS project (to support drug discovery) and the PharmaSea initiative (to identify novel natural products from the ocean). We will also provide an overview of our activities to perform data mining of public patent collections and examine what can be done with the data. We are presently extracting physicochemical properties and textual forms of NMR spectra and, with the resulting data, are building predictive models (for melting points at present) and assembling a large NMR spectral database containing many hundreds of thousands of spectral-structure pairs. Our experiences to date have demonstrated that we are working at the edge of current algorithmic and computing capabilities for predictive model building, with over a quarter of a million melting points producing a matrix of over 200 billion descriptors. Our work to produce the NMR spectral database will necessitate batch processing of the data to examine consistency between the spectral-structure pairs and other forms of data validation. The intention is to take our experiences in this work applied to a public patents corpus and apply it to the RSC back file of publications to mine data and enable new paths to the discoverability of both data and the associated publications.
Towards Automated AI-guided Drug Discovery LabsOla Spjuth
Presentation by Ola Spjuth (Uppsala University and Scaleout Systems) on 2019-10-16 at Swedish e-Science Academy 2019 in Lund, Sweden.
Research website at Uppsala University: https://pharmb.io
Scaleout Systems: https://scaleoutsystems.com
Enhancing collaboration in informatics solutions
Now more than ever, the need for establishing connections and closer collaboration is a priority for many organisations. This webinar will highlight how Medicines Discovery Catapult is looking to approach the issue of ensuring the right problems are being tackled by the right experts.
Presented by Mark Davies on 30th April 2020
Validating microbiome claims – including the latest DNA techniquesEagle Genomics
Abel Ureta-Vidal, Founder and CEO of Eagle Genomics, discusses how advanced DNA techniques help us to identify and characterise the microbiome, leading us to ways to prove cosmetic claims at the in-cosmetics formulation summit, 25th October 2017.
Drug discovery and development is a long and expensive process over time has notoriously bucked Moore's law that it now has its own law called Eroom's Law named after it (the opposite of Moore). It is estimated that the attrition rate of drug candidates is up to 96% and the average cost to develop a new drug has reached almost $2.5 billion in recent years. One of the major causes for the high attrition rate is drug safety, which accounts for 30% of drug failures. Even if a drug is approved in market, it could be withdrawn due to safety problems. Therefore, evaluating drug safety extensively as early as possible becomes all the more important to accelerate drug discovery and development. This talk provides a high-level overview of the current process of rational drug design that has been in place for many decades and covers some of the major areas where the application of AI, Deep learning and ML based techniques have had the most gains. Specifically, this talk covers a variety of drug safety related AI and ML based techniques currently in use which can generally divided into 3 main categories: 1. Classification 2. Regression 3. Read-across. The talk will also cover how by using a hierarchical classification methodology you can simplify the problem of assessing toxicity of any given chemical compound. We will also address recent progress of predictive models and techniques built for various toxicities. It will also cover some publicly available databases, tools and platforms available to easily leverage them. We will also compare and contrast various modeling techniques including deep learning techniques and their accuracy using recent research. Finally, the talk will also address some of the remaining challenges and limitations yet to be addressed in the area of drug safety assessment.
Step by step tutorial for conducting GO enrichment analysis and then creating a network from the results.
Material from the UC Davis 2014 Proteomics Workshop.
See more at: http://sourceforge.net/projects/teachingdemos/files/2014%20UC%20Davis%20Proteomics%20Workshop/
2020.04.07 automated molecular design and the bradshaw platform webinarPistoia Alliance
This presentation described how data-driven chemoinformatics methods may automate much of what has historically been done by a medicinal chemist. It explored what is reasonable to expect “AI” approaches might achieve, and what is best left with a human expert. The implications of automation for the human-machine interface were explored and illustrated with examples from Bradshaw, GSK’s experimental automated design environment.
With the explosion of interest in both enhanced knowledge management and open science, the past few years have seen considerable discussion about making scientific data “FAIR” — findable, accessible, interoperable, and reusable. The problem is that most scientific datasets are not FAIR. When left to their own devices, scientists do an absolutely terrible job creating the metadata that describe the experimental datasets that make their way in online repositories. The lack of standardization makes it extremely difficult for other investigators to locate relevant datasets, to re-analyse them, and to integrate those datasets with other data. The Center for Expanded Data Annotation and Retrieval (CEDAR) has the goal of enhancing the authoring of experimental metadata to make online datasets more useful to the scientific community. The CEDAR work bench for metadata management will be presented in this webinar. CEDAR illustrates the importance of semantic technology to driving open science. It also demonstrates a means for simplifying access to scientific data sets and enhancing the reuse of the data to drive new discoveries.
Considerations and challenges in building an end to-end microbiome workflowEagle Genomics
Many of the data management and analysis challenges in microbiome research are shared with genomics and other life-science big-data disciplines. However there are aspects that are specific: some are intrinsic to microbiome data, some are related to the maturity of the field, with others related to extracting business value from the data.
The phrase “Big Data” is generally used to describe a large volume of structured and/or unstructured data that cannot be processed using traditional database and software techniques. In the domain of chemistry the Royal Society of Chemistry certainly hosts large structured databases of chemistry data, for example ChemSpider, as well as unstructured content, in the form of our collection of scientific articles. Our research literature provides value to their readership and, at present, as an example of one of our databases, ChemSpider is accessed by many tens of thousands of scientists every day. But do these collections constitute “Big Data” or is it the potential which lies within the collections that can contribute to the Big Data movement. This presentation will discuss our activities to contribute both data, and service-based access to our data sets, to support grant-based projects such as the Innovative Medicines Initiative Open PHACTS project (to support drug discovery) and the PharmaSea initiative (to identify novel natural products from the ocean). We will also provide an overview of our activities to perform data mining of public patent collections and examine what can be done with the data. We are presently extracting physicochemical properties and textual forms of NMR spectra and, with the resulting data, are building predictive models (for melting points at present) and assembling a large NMR spectral database containing many hundreds of thousands of spectral-structure pairs. Our experiences to date have demonstrated that we are working at the edge of current algorithmic and computing capabilities for predictive model building, with over a quarter of a million melting points producing a matrix of over 200 billion descriptors. Our work to produce the NMR spectral database will necessitate batch processing of the data to examine consistency between the spectral-structure pairs and other forms of data validation. The intention is to take our experiences in this work applied to a public patents corpus and apply it to the RSC back file of publications to mine data and enable new paths to the discoverability of both data and the associated publications.
Towards Automated AI-guided Drug Discovery LabsOla Spjuth
Presentation by Ola Spjuth (Uppsala University and Scaleout Systems) on 2019-10-16 at Swedish e-Science Academy 2019 in Lund, Sweden.
Research website at Uppsala University: https://pharmb.io
Scaleout Systems: https://scaleoutsystems.com
Enhancing collaboration in informatics solutions
Now more than ever, the need for establishing connections and closer collaboration is a priority for many organisations. This webinar will highlight how Medicines Discovery Catapult is looking to approach the issue of ensuring the right problems are being tackled by the right experts.
Presented by Mark Davies on 30th April 2020
Validating microbiome claims – including the latest DNA techniquesEagle Genomics
Abel Ureta-Vidal, Founder and CEO of Eagle Genomics, discusses how advanced DNA techniques help us to identify and characterise the microbiome, leading us to ways to prove cosmetic claims at the in-cosmetics formulation summit, 25th October 2017.
Drug discovery and development is a long and expensive process over time has notoriously bucked Moore's law that it now has its own law called Eroom's Law named after it (the opposite of Moore). It is estimated that the attrition rate of drug candidates is up to 96% and the average cost to develop a new drug has reached almost $2.5 billion in recent years. One of the major causes for the high attrition rate is drug safety, which accounts for 30% of drug failures. Even if a drug is approved in market, it could be withdrawn due to safety problems. Therefore, evaluating drug safety extensively as early as possible becomes all the more important to accelerate drug discovery and development. This talk provides a high-level overview of the current process of rational drug design that has been in place for many decades and covers some of the major areas where the application of AI, Deep learning and ML based techniques have had the most gains. Specifically, this talk covers a variety of drug safety related AI and ML based techniques currently in use which can generally divided into 3 main categories: 1. Classification 2. Regression 3. Read-across. The talk will also cover how by using a hierarchical classification methodology you can simplify the problem of assessing toxicity of any given chemical compound. We will also address recent progress of predictive models and techniques built for various toxicities. It will also cover some publicly available databases, tools and platforms available to easily leverage them. We will also compare and contrast various modeling techniques including deep learning techniques and their accuracy using recent research. Finally, the talk will also address some of the remaining challenges and limitations yet to be addressed in the area of drug safety assessment.
Step by step tutorial for conducting GO enrichment analysis and then creating a network from the results.
Material from the UC Davis 2014 Proteomics Workshop.
See more at: http://sourceforge.net/projects/teachingdemos/files/2014%20UC%20Davis%20Proteomics%20Workshop/
2020.04.07 automated molecular design and the bradshaw platform webinarPistoia Alliance
This presentation described how data-driven chemoinformatics methods may automate much of what has historically been done by a medicinal chemist. It explored what is reasonable to expect “AI” approaches might achieve, and what is best left with a human expert. The implications of automation for the human-machine interface were explored and illustrated with examples from Bradshaw, GSK’s experimental automated design environment.
DAS SOTI Presented by Nextmark: What We Love, Hate and Desire in Our Digital ...Digiday
What do we love and hate about our jobs in the digital media business? How happy are we? What drives our happiness? NextMark’s Joe Pych will present the results from Digiday’s first ever Digital Media Job Satisfaction Survey. The results may surprise you!
Presenter: Joe Pych, CEO, NextMark @jpych
Green chemistry in chemical reactions: informatics by designAlex Clark
Chemical informatics technology can be of assistance to chemists for describing reactions in numerous ways, including calculating green chemistry metrics such as process mass intensity, E-factor and atom economy. To facilitate this, chemical reactions have to be described in more precise detail than is the norm for most chemists. There are also numerous practical ways to add more green chemistry functionality to lab notebooks, such as enumerating searchable reaction transforms for environmentally favourable reactions, automatically looking up toxicity and hazard information, and others which are mentioned in the slides.
This presentation was given at the Green Chemistry & Engineering conference in 2015 (Americal Chemical Society Green Chemistry Insititute).
The importance of data curation on QSAR Modeling: PHYSPROP open data as a cas...Kamel Mansouri
This presentation highlighted how data curation impacts the reliability of QSAR models. We examined key datasets related to environmental endpoints to validate across chemical structure representations (e.g., mol file and SMILES) and identifiers (chemical names and registry numbers), and approaches to standardize data into QSAR-ready formats prior to modeling procedures. This allowed us to quantify and segregate data into quality categories. This improved our ability to evaluate the resulting models that can be developed from these data slices, and to quantify to what extent efforts developing high-quality datasets have the expected pay-off in terms of predicting performance. The most accurate models that we build will be accessible via our public-facing platform and will be used for screening and prioritizing chemicals for further testing.
The Data Driven University - Automating Data Governance and Stewardship in Au...Pieter De Leenheer
Data Governance and Stewardship requires automation of business semantics management at its nucleus, in order to achieve data trust between business and IT communities in the organization. University divisions operate highly autonomously and decentralized, and are often geographically distributed. Hence, they benefit more from an collaborative and agile approach to Data Governance and Stewardship approach that adapts to its nature.
In this lecture, we start by reviewing 'C' in ICT and reflect on the dilemma: what is the most important quality of data being shared: truth or trust? We review the wide spectrum of business semantics. We visit the different phases of growing data pain as an organization expands, and we map each phase on this spectrum of semantics.
Next, we introduce our principles and framework for business semantics management to support Data Governance and Stewardship focusing on the structural (what), processual (how) and organizational (who) components. We illustrate with use cases from Stanford University, George Washington University and Public Science and Innovation Administrations.
[Etude] Entrepreneurs de la Tech : qui sont-ils?FrenchWeb.fr
Qui est l'entrepreneur de la Tech en France? Comment a-t-il développé son projet? Quelles sont ses aspirations? A quel moment sautent-ils le pas…? Frenchweb a souhaité comprendre qui sont les entrepreneurs du digital en France.
Is Pay Hindering Your Company’s Performance?
A culture of performance is one where success patterns have taken root throughout an organization. The company is winning and you see it manifest in every part of the business. However, for too many companies, the culture is not “firing on all cylinders.” Performance is lagging. As a result, breakthrough growth remains out of reach.
Pay can either drive or inhibit the success patterns that fuel business growth. If your company’s rewards strategy is hindering more than enabling a performance culture, you will not want to miss this presenation
Machine learning, health data & the limits of knowledgePaul Agapow
Lecture for Imperial College London's MSc in Health Data Analytics, critiquing a recent paper on COVID diagnosis and moving out to talk about good practices (& limits) in ML and model building
Atul Butte's presentation to the Association of Medical School Pediatric Department Chairs #AMSPDC on March 3, 2018.
Some pre-publication data slides have been removed from this deck.
"Using Data Science to Design Effective Precision Preventative Behavioral Med...Hyper Wellbeing
"Using Data Science to Design Effective Precision Preventative Behavioral Medicine" - Ryan Quan (Data Scientist, Omada Health)
Delivered at the inaugural Hyper Wellbeing Summit, 14th November 2016, Mountain View, California.
For more information including details of subsequent events, please visit http://hyperwellbeing.com
The summit was created to foster a community around an emerging industry - Wellness as a Service (WaaS). Consumer technologies, in particular wearables and mobile, are powering a consumer revolution. A revolution to turn health and wellness into platform delivered services. A revolution enabling consumer data-driven disease risk reduction. A revolution extending health care past sick care towards consumer-led lifelong health, wellness and lifestyle optimization.
WaaS newsletter sign-up http://eepurl.com/b71fdr
@hyperwellbeing
Reproducibility, argument and data in translational medicineTim Clark
Failures in reproducibility and robustness of scientific findings are explored from statistical, historical, and argumentation theory perspectives. The impact of false positives in the literature is connected to failures in T1 and T2 biomedical translation, and is shown to have a significant impact on the costs of therapeutic development and availability of needed treatments to the public. Technological and social approaches to resolve these issues are presented. "Reproducibility" initiatives are critiqued as unsustainable and non-authoritative; improved requirements and methods for scientific communication of findings including data, methods and material are supported as the best approaches for improved reproducibility.
Journal club and talk given to Health Data Analytics MSc, February 2023. Reflecting on how to do good machine learning over biomedical data, the pitfalls and good practices
Similar to Why are we still doing industrial age drug (20)
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
This presentation from June 12 2020 gives a brief overview of my experience of 15 years of applying for government grants to fund small companies. Prior to this I had no experience of applying for such grants. The bottom line for rare disease groups / families is find a scientist that can do this or assist you. please also see www.collaborationspharma.com
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
Slides from AAPS Careers session by Maren Katherina Preis, Kyle Bagin, Sean Ekins
Provides some clear steps on how you could use social media to help your career.
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
Oral presentation at 2017 ACS in DC - given by Kimberley Zorn
co-authors include Mary A. Lingerfelt, Alex M. Clark, Sean Ekins
for more details see www.collaborationspharma.com
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
Presentation given at the AAPS 2016 conference in Denver. Some of the slides are from AAPS, Some from Kudos and some from Figshare. One slide is from Tony Williams. All slides used with permission.
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...Sean Ekins
A perspective on 12 yrs of CDD and developing products and collaborations.
A presentation given at the ACS meeting in San Diego - small business section
This presentation summarizes some early efforts on an open drug discovery collaboration between scientists in Brazil and the US. The amazing virus images were created by John Liebler and can be licensed from him http://www.artofthecell.com/animation/will-the-real-zika-virus-please-stand-up
The homology models were created with Swiss Model by Sean Ekins:
Marco Biasini, Stefan Bienert, Andrew Waterhouse, Konstantin Arnold, Gabriel Studer, Tobias Schmidt, Florian Kiefer, Tiziano Gallo Cassarino, Martino Bertoni, Lorenza Bordoli, Torsten Schwede. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research; (1 July 2014) 42 (W1): W252-W258; doi: 10.1093/nar/gku340.
Arnold K., Bordoli L., Kopp J., and Schwede T. (2006). The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22,195-201.
Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T (2009). The SWISS-MODEL Repository and associated resources. Nucleic Acids Research. 37, D387-D392.
Guex, N., Peitsch, M.C., Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis, 30(S1), S162-S173.
Ensuring Chemical Structure, Biological Data and Computational Model Quality
A talk given at SLAS 2016 mon Jan 25th in San Diego
covers published work and recent forays with BIA 10-2474
Pros and cons of social networking for scientistsSean Ekins
Over the past 4 years I have been using social networking tools for scientists more inspired by Antony Williams. I realized I am using many tools and there are pros and cons of them. Here is my brief summary.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
1. Why Are We Still Doing Industrial
Age Drug Discovery For Neglected
Diseases in The Information Age?
Sean Ekins
Collaborations
In
Chemistry,
Fuquay Varina, NC
5. Still valuing the 70’s BLOCKBUSTER
model but its changing
And of course no treatments for neglected diseases are blockbusters
6. The Old School vs New School
screening
•
•
•
New School - Many hurdles before in vivo lots of data Yet HTS started in the 1980’s!!
Old school – go in vivo at outset – little data
New database technologies work well for
New school but ..Old School type data ?
7. Drug Discovery Archeology
• Still a heavy emphasis on
“testing” “doing “ rather
than ‘learning’
• Mining data and historic
data will increase in value
• Data becomes a
repurposing opportunity
• How do we position
databases for this?
• What about neglected
diseases?
10. But what about small data?
• In some cases its all we have
• In vivo data is not high throughput
V
• Small data builds networks
http://smalldatagroup.com/
13. Big Data: Screening for New Tuberculosis Treatments
Tested >300,000 molecules
>1500 active and non toxic
Tested ~2M
Published 177
How many will become a new drug?
How do we learn from this big data?
14. Small data: Mouse In vivo model data
«Tuberculosis» 333 papers in PubMed
«Malaria» 301 papers in PubMed
15. Can combining Big and Small
data (in vitro, in vivo) help us
find better compounds,
faster ?
Avoid testing as
many molecules
16. In vitro data
In vivo data
Target data
ADME/Tox data & Models
Connecting data/tools like a TB Spider
Drug-like scaffold creation
TB Prediction Tools
TB Publications
17. Where are the New TB drugs to be found?
In vivo actives (yellow)
23. Hunting High and Low for new
molecules to test
We need to search
sources..
From the Oceans…
To the ground
To the trees
To the air..
And do it virtually
24. Time for the New New School
Models replace testing
Testing = confirming
Predict in vivo and in vitro in parallel
MULTIDIMENSIONAL
Save resources
